MImETIC INDiRECT – MIcrovascularizED Tumour-on-chip for Cellular ImagiNg of Drug Response and Cell motility



The current drug discovery and clinical trials pipeline is broken 1, where ever diminishing resources are expended at considerable costs on less than optimal and often non-standardised biological models (commercial cell lines, animal models, etc.) 23 for diminishing returns in attempts to discover and develop new therapies for the increasing incidences of cancers worldwide 4. Various strategies, such as personalized medicine and organ-on-chip approaches, have been suggested as a possible solution for the inherent logistical (e.g.: financial costs, study design, etc.) and biological (e.g.: genetic similarity, high toxicity, etc.) barriers to finding successful and reduced toxicity therapeutic candidates in the current drug discovery pipeline.

Personalized medicine refers to any approach which uses the biological material (cells, tissues) of the individual to design a unique treatment regimen which will benefit this individual optimally. Typically, the abovementioned approach can include evaluating the suitability of various chemotherapies, immunotherapies and gene therapies on their own or in combination. Organ-on-chip approaches describes a technological approach where human cells, commercial or patient derived, are kept viable in a controlled environment which can mimic nutrient/waste/gas exchange, typically using microfluidics approaches.  In such a manner, the human physiology is near-perfectly mimicked, allowing for the cells/tissues to respond as if they were still inside the human body. Organ-on-chip approaches is a multidisciplinary subset of personalized medicine, with applications in other related fields, providing potential routes to fast-track drug discovery/development as well as toxicological assessment and implementation phases. These technologies are however, in most cases, still in their infancy and require standardization to be accepted fully by the scientific consensus and properly implemented.

Proof of principle work demonstrating the future applications of organ-on-chip approaches and the application in personalized medicine, drug discovery and toxicity studies are demonstrated by: (i) a diaphragm-like lung organ-on-chip mechanically and physiologically mimicking inhaling/exhaling coupled with respiration 4; (ii) a single multi-chamber chip intestine-liver-skin-kidney organ(s)-on-chip for mimicking excretory multiorgan toxicity and drug response studies 5; and (iii) a LEGO®-based “plug-and-play” modular organ-on-chip system for serial/parallel modular selectivity 6. Despite the versatility of organ-on-chip technologies, cancer applications are mostly in diagnostics, with: (i) circulating cancer cells 6 entrapment on-chip to grow spheroids/organoids on-chip or (ii) biomarker 7 entrapment on-chip for analytical assays.


Current organ-on-chip systems allow mostly for single parametric (e.g. drug response only or metastases only) analysis of tumours. Multi-parametric research organ-on-chip cancer models can, in addition to the focus investigation, facilitate the study of: (i) lung cancer cell and lung fibroblast intercellular/ECM interactions as well as cell motility by using mixed cell hydrogel bioprinting organ-on-chip 8; (ii) micro-vascularized complex tissue micro-tumours in a high-throughput 96-well hydrostatic flow format organ-on-chip 9; and (iii) incorporation of oxygen sensors 10 to regulate aerobic/anaerobic tumour biology organ-on-chip. A landmark study by Bower et al demonstrated head-and-neck cancer 11 organ-on-chip models as potential predictive tools for chemotherapy personalization, successfully keeping tissues viable for 48h.

Unfortunately, none of the current MFOC technologies provide standardised or accessible systems for comparative studies.



Contact Us






The design of a multiparametric organ-on-chip toolkit with customizable layout in a high-throughput design will enable various biochemical and physiological parameters (e.g. drug response, toxicity, acquired drug resistance cell motility, chemotaxis) to be studied simultaneously using real-time live imaging microscopy. Proof-of-concept work will use cancerous as well as non-cancerous cells to create organs-on-chips as target sites for multiparametric studies, with downstream flow capture to further analysis.

MImETIC INDiRECT H2020 Cherry Biotech
In addition to the simultaneous detection of drug response and cellular motility as a response function of the avoidance of cell death in real-time, it will be possible to determine whether secondary tumours successfully form in downstream flow on-chip as well as whether these tumours present with acquired drug resistance.

The potential application of a customizable toolkit such as mentioned above is for the academic and the clinician who has an interest to determine in a facile top-down approach, if a compound has an (i) anti-cancer or toxic effect; (ii) if cell motility (metastasis) is induced in response to therapy and (iii) whether the motile cells can be treated with a similar or alternate therapeutic agent. The transferability of the above-mentioned model will then be evaluated using biopsy tissue organ-on-chip applications for personalized medicine approaches.


The European Commission actively promotes innovation and technological development by large economic efforts in strategic sectors, however there is a poor translation for most cases towards entrepreneurship and social impact. The worldwide relevance of finding a standardized organ-on-chip toolkit for use in personalized medicine for cancer diagnostics and therapeutics, using patient derived explants, circulating cells from liquid biopsies or commercial cell lines will enable more proactive and robust approaches to optimize the drug discovery/development pipeline, toxicity studies in an ethical and animal free manner, resulting in more effective resource management in R&D. Additionally, a standardized toolkit for personalized cancer medicine and organ-on-chip will allow researchers and clinicians to talk the same language when translating results between the bench and the clinic. Project results will be disseminated, where possible, in academic and non-academic journals as well as conferences to network with industry role-players.

The project manager: Dr. CJF (Francois) Taute

Dr. Taute is a Marie Curie IF Fellow (2019 – 2021), whose research focus is to adapt and discover cutting edge technologies for implementation in personalized cancer diagnostics and therapy.

Dr. Taute will be engaged in various activities surrounding the topics of technology entrepreneurship, intellectual property management and R&D, with a focus on the greater good implementation strategies of technologies in the developing world.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No  840577

Disclaimer: this content reflects only the author’s view and the EU Agency is not responsible for the information it contains.


  1. https://endpts.com/fdas-janet-woodcock-the-clinical-trials-system-is-broken/
  2. Katt et al., In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Frontiers in Bioengineering and Biotechnology, 2016.
  3. Mak et al., Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res. 2014. 6(2)114-118.
  4. https://www.who.int/news-room/fact-sheets/detail/cancer
  5. Stucki et al., A lung-on-a-chip array with an integrated bio-inspired respiration mechanism. Lab Chip. 2015, 15:1302-1310.
  6. Maschmeyer et al., A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip. 2015. 15:2688-2699.
  7. Owens, C.E. and Hart, A.J., High-precision modular microfluidics by micromilling of interlocking injection-molded blocks. Lab Chip. 2018. 18:890-901.
  8. Guo et al., Diagnostics value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget. 2018. 9(7):7522-7533.
  9. Fang et al., Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. PLOSOne. 2017. 12(4):e0175050.
  10. Mondal et al., Bioprinted (3D) co-cultured spheroids with NSCLC PDX cells and cancer associated firbroblasts (CAFs) using alginate/gelatin hydrogel. Cancer Research. 2018. DOI:10.1158/1538-7445.AM2018-5018.
  11. Phan et al., A vascularized and perfused organ-on-chip platform for large-scale drug screening applications. Lab Chip. 2017.
  12. De Wever et al., Heterocellulaer 3D scaffolds as biomimetic to recapitulate the tumour microenvironment of peritoneal metastases in vitro and in vivo. Cancer Research. 2018. DOIL10.1158/1538-7445.AM2018-5027.
  13. Bower et al., Maintenance of head and neck tumour on-chip: gateway to personalized treatment. Future Sci. OA. 2017. 3(2):FSO174